Adrian Gottschalk serves as the President and Chief Executive Officer of Foghorn Therapeutics. Bringing extensive leadership experience from major biopharmaceutical enterprises such as Biogen—where he managed late-stage neurodegeneration and global commercial strategy portfolios—he guides Foghorn's corporate vision, clinical development pipelines, and strategic scientific collaborations.